The 22 articles summarized in this compendium were identified using PubMed and Google Scholar databases incorporating search terms such as “HYDRUS Microstent” and “minimally-invasive glaucoma surgery.” Articles were included when they were published between January 1, 2012 and March 31, 2022 and contained preclinical or clinical research relevant to the Hydrus® Microstent for its indicated use in MIGS in conjunction with cataract surgery. Only manuscripts published in peer-reviewed journals and available in English were included in this compendium. Results with devices that are not approved by the FDA or with off-label indications were not included. At Alcon, our surgical medical device products, such as the Hydrus® Microstent, are designed, manufactured and marketed with a body of science developed through rigorous bench research and clinical studies. As the body of knowledge behind Alcon’s products grows, so does the challenge of making our customers aware of its depth. Our medical affairs organization is thus focused on both high-quality data generation and its communication to the clinical community. High-quality scientific publications are essential to convey the clinical community’s knowledge and experience with the latest technology. This clinical science compendium provides a consolidated view of peer- reviewed publications for Hydrus® Microstent, a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for adult primary open-angle glaucoma patients by reestablishing flow through Schlemm’s canal, the eye’s natural outflow pathway. In January 2022, Alcon Vision, LLC acquired Ivantis, Inc., the developer of Hydrus®. In addition to exploring this compendium, we encourage you to visit Alcon’s Medical Affairs website—AlconScience.com—to learn more about how medical science matters to us. Beyond scientific publications relating to Alcon’s portfolio, you will find more information on independent medical educational grants, teaching facility equipment placement, and areas of interest for investigator-initiated trials.